Corxel, an obesity drugmaker, to go public via SPAC deal

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 26 Oct, 19:17 UTC

Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets.

science

Sources

• T2Corxel, an obesity drugmaker, to go public via SPAC dealBioPharma Dive / Healthcare Dive / MedTech Dive26 Oct, 19:17